DNR

(redirected from Daunorubicin)
Also found in: Dictionary, Medical, Wikipedia.
Related to Daunorubicin: doxorubicin
AcronymDefinition
DNRDo Not Resuscitate
DNRDepartment of Natural Resources
DNRDigital Noise Reduction
DNRDo Not Remove
DNRDo Not Reply
DNRDynamic Noise Reduction
DNRDomain Name Registration
DNRDotnetRocks (.NET software radio show)
DNRDeutsche Naturschutzring (German: German Nature Ring)
DNRDid Not Report
DNRDo Not Remember (adoption)
DNRDo Not Reduce
DNRDo Not Reproduce
DNRDomain Name Resolver
DNRDialed Number Recorder
DNRDo Not Revert (Ciena)
DNRDo Not Revive (less common)
DNRDry Natural Rubber
DNRDo Not Refrigerate
DNRDynamic Network Routing
DNRDrive Not Ready (computer error)
DNRDepartment of National Revenue (Canadian)
DNRDrop And Run (medical)
DNRDirector Naval Reserves
DNRDistance-To-Noise Ratio
DNRDepartment of Naval Research
DNRDo Not Reorder
DNRDiazonaphthoquinone Novalac Resist
DNRDigital Network Radio
DNRData Network Redesign
DNRDundee Newtyle Railway
DNRDirector of Naval Reactors (US Navy)
DNRDaunorubicin
DNRData Network Report
References in periodicals archive ?
According to the tests, this system significantly decreases the side effects of daunorubicin drug in the control cells, and it increases its therapeutic effects in the target cells in comparison with the drug without carriers.
The scientists bound the surfaces of nanodiamonds with Daunorubicin, and the hybrid nanodiamond-drug complexes were introduced to leukemic cells.
To start the experiments, 10 [micro]M R123 or 50 [micro]M daunorubicin final concentrations were added to the donor side (apical side for apical to basolateral (a-b) experiment and basolateral side for basolateral to apical (b-a) experiment) and then incubated at 37 [degrees]C.
Oligonucleosomal DNA fragments were isolated from the cytosolic fraction of hyperatomarin or daunorubicin treated SKW-3 cells after 24h continuous exposure, and analysed by gel eletrophoresis as described elsewhere (Konstantinov et al.
Speaking about the European Commission orphan medicinal product designation for liposomal daunorubicin, Mark Scrutton, President of Galen, commented: "We are delighted about the designation of liposomal daunorubicin as an orphan medicinal product for the treatment of acute myeloid leukaemia, a life-threatening disease.
They treated these mice with daunorubicin, doxorubicin or saline once a day for five days and measured tumor size.
Another randomized, open-label Phase 2b study, comparing CPX-351 to standard of care conventional cytarabine and daunorubicin (7+3 regimen) enrolled patients between the ages of 60-75 years with newly-diagnosed AML at 18 sites in the United States and Canada.
The findings presented at ASH demonstrate that CPX-351, through the targeted delivery of a consistent and synergistic ratio of cytarabine and daunorubicin, results in improved clinical outcomes compared to standard salvage therapy," stated Dr Cortes.
This open-label, single arm, Phase 2 study measured the effects of VYXEOS on cardiac repolarization during the first induction cycle and correlated electrophysiologic changes, as measured by the QT/QTc interval, with a detailed pharmacokinetic assessment of cytarabine and daunorubicin and their metabolites using exposure response modeling methodology.
8,022,279 covers the key composition features of CPX-351, a liposome formulation that co-encapsulates cytarabine and daunorubicin at a synergistic 5:1 molar ratio.
The Phase 3 study compares VYXEOS versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3) as first-line therapy in older patients with high-risk (e.
The results were based on a subgroup analysis, after 12 months of follow-up, in a randomized Phase 2b trial that compared CPX-351 to conventional cytarabine and daunorubicin (7+3 regimen), the current standard of care (ASCO Abstract #6519).